formed to quantify the uncertainty around the mean estimates and costeffectiveness acceptability curves were presented. In addition, a number of univariate sensitivity analyses were performed on deterministic variables. Results: At 5 months, 3.1% (95% UI [uncertainty interval] -9.7%, +15.8%) more patients had NBP, and 0.003 (95% UI -0.005, +0.010) more QALYs were generated in the experimental strategy. A statistically significant lower percentage of patients had a dose escalation in the experimental strategy. Irrespective of the ceiling ratio for cost effectiveness, the cost-effectiveness probability was between 75% and 80% for the analysis from the healthcare perspective using proportion of patients with NBP as the outcome parameter. For the analysis from the societal perspective using QALYs as the outcome parameter, this probability was between 45% and 51%. Conclusion: For a time horizon of 5 months, a difference in both cost and effect could not be detected between an adherence-improving programme compared with usual care for hypertensive patients. The probability that the adherenceimproving programme is cost effective is at best moderate. Moreover, the costeffectiveness result is surrounded with considerable uncertainty and large-scale implementation warrants additional research into the economic consequences of this intervention. Patients may benefit from the use of a MEMS monitor in situations where BP targets are not reached because of suspected non-adherence and both patient and GP are reluctant to increase the dose or number of antihypertensive drugs.
For pharmacological treatment to be beneficial, it total €234 million (year 1998 values), which is is of the utmost importance that patients adhere to 0.7% of the total healthcare budget in 1998.
[4] Deprescribed medication. Failure to adhere to pre-velopment of patient management strategies that are scribed medication regimens increases the risk of targeted at increasing patients' own role in improvillness [1] and total healthcare costs.
[2] Non-adherence ing blood pressure (BP) control, may lead to cost is common and has been identified as a major public containments and therefore deserve interest. health problem.
[3] The proportion of patients that do Several methods to monitor and improve adhernot adhere to treatment ranges from considerable to ence have been used, e.g. self-reported adherence, high and depends on the class of drug. It is estimated prescription renewal, counting pills, or biological to vary between 33% for cholesterol-lowering markers. All these methods have their limitaagents and 87% for inhaled corticosteroids. [4] tions, [8, 9] and a number of systematic reviews have Hypertension is one of the chronic conditions demonstrated that no single intervention has where non-adherence needs attention. It has been emerged as superior. [10] [11] [12] Several years ago, the estimated that only approximately 50-70% of pa-Medication Event Monitoring System (MEMS; Aartients with hypertension take their medication ac-dex Corp., Geneva, Switzerland) became available, cording to the prescribed regimen. [5, 6] Because of the which is a drug container and cap equipped with a high prevalence of the disease, which has been microchip that registers the date and time of each estimated to be on average 44% in six European opening container. [13] It seems to be an effective tool countries and 28% in North America, [7] economic to identify non-adherent patients. [14] [15] [16] [17] [18] [19] [20] [21] Moreover, consequences of non-adherence may be substantial. electronic monitoring has been shown to improve In The Netherlands, superfluous expenses associat-adherence in hypertensive patients, [14, 15] in psychiated with treatment non-adherence are estimated to ric patients, [22, 23] in those with obstructive lung dis-ease [24] and in women participating in a smoking they had a diagnosis of hypertension that was inadecessation trial. [25] The consequences of non-adher-quately controlled despite the use of antihypertenence with pharmacotherapies have been largely ne-sive drugs. Uncontrolled BP was defined as a systolglected in the medical and health economic litera-ic BP (SBP) ≥160mm Hg and/or diastolic BP (DBP) ture. [26] Although the cost effectiveness of a number ≥95mm Hg. [33] In diabetic patients, high BP was of adherence-enhancing interventions in hyperten-defined as ≥150mm Hg SBP and ≥85mm Hg DBP. sion has been assessed, [27] [28] [29] [30] [31] the cost effectiveness of Furthermore, there had to be an indication for treatelectronic monitoring as a tool to improve adherence ment escalation, defined as an increase in dosage, remains to be elucidated. addition or change of antihypertensive drugs. Patients were excluded when treatment was adjusted The objective of the present study was to assess because of adverse effects of current medication, or the cost effectiveness of an adherence-improving when patients insisted on using dose organisers. programme using the MEMS in hypertensive pa-
Patients not eligible for the study also included those tients in the primary care setting, compared with who were institutionalised and those not managing usual care. Differences in healthcare and societal their drug intake themselves. costs were related to the difference in effects in terms of normalised BP (NBP) and generic quality
The power calculation was based on the proporof life (QOL), respectively.
tion of patients with a normalised BP (NBP). Assuming a significance level of 5%, NBP in 50% of Methods patients in the usual care strategy, and a randomisation ratio of 2 : 1, it was calculated that 167 patients were needed in the experimental care strategy and
Study Design
83 patients in the usual care strategy in order to This economic evaluation has been performed detect an increase in the proportion of patients with alongside TULIPA (The Utrecht Limburg Initiative an NBP of 20%, with a power of 85%. on Patient adherence with Antihypertensives) study, [32] a randomised clinical trial with two paralIntervention lel groups. Patients were randomly assigned to either the experimental or usual care strategies, acThe intervention provided to the patients in the cording to a randomisation ratio of 2 : 1. This ratio experimental strategy consisted of adherence moniwas employed in order to allow for a reliable estima-toring and adherence-improving training only for tion of the proportion of poor adherers in the experi-patients with unsatisfactory adherence. In the expermental care strategy. Randomisation was performed imental strategy, antihypertensive medication was centrally by telephone through the Trial Coordinat-monitored for 8 weeks without medication changes. ing Centre. For each GP a random allocation scheme For each prescribed drug, patients received a MEMS was generated using computer-generated random container and cap. Patients were informed that the permuted blocks with a block size of six. Both MEMS cap recorded the date and time of each patients and the referring GPs were unaware of the opening of the container. After the first evaluation randomisation sequence. Patients were followed for period of 2 months, adherence data were 5 months. The Institutional Review Board granted downloaded to a personal computer using dedicated ethical approval for the study. A written informed software, and medication adherence was determined consent form was obtained from each enrolled pa-by a GP assistant. Adherence was defined as the tient.
proportion of days with the number of doses taken as prescribed, e.g. correct dosage. For all prescribed
Patients and Methods medication, patients taking ≥85% of prescribed Patients were recruited by 43 GPs in the southern doses were considered adherent. In patients with area of The Netherlands. Patients were eligible if unsatisfactory adherence, no dose escalation or medication adjustment took place and irrespective each patient was obtained from the patient's pharof their BP, electronic monitoring was continued for macist. We distinguished between direct healthcare another 3 months. Patients with satisfactory adher-costs, direct non-healthcare costs and indirect costs. ence who still had uncontrolled BP after 2 months of Details concerning these cost categories are electronic monitoring, were referred to their GP who presented in table I. decided whether or not adjustment of medication
The intervention costs consisted of costs of inwas indicated.
struction, electronic monitoring costs and training Additionally, those patients with unsatisfactory aimed at improving adherence. These costs were adherence received training to manage adherence, determined based on the following assumptions:
provided by a GP assistant in three sessions of 15 • Patients were given instructions on how to use minutes duration. The training consisted of a review the monitor by the GP assistant during the first of the adherence report with the patient. The goal visit for 15 minutes.
was to give insight into their own dosing history, to • Relevant to the electronic monitoring costs are identify periods of suboptimal adherence, to explore the costs of the MEMS container and cap, the reasons for suboptimal adherence and to define communicator and software for reading out of the 'cues' linked to drug taking. In the usual care stratemonitor, as well as personnel costs for packaging gy, antihypertensive medication was intensified by the drug in the electronic monitor and reading out addition or change of antihypertensive drugs if necof the monitors.
essary, and regular drug containers and caps were • Patients were assumed to have one GP consultaused. tion, during which the patient was provided with the monitor container and cap. Subsequently, the Costs pharmacist assistant filled caps with electronic monitors for every prescribed drug. Costs were quantified from both the healthcare
• It was assumed that re-use of the monitor cap was and societal perspectives. The healthcare perspecallowed, but that monitor containers (standard tive takes only medical costs into account (either bottle containers to which the monitor cap can be paid for by insurance or by the patients themselves).
fitted) were for single use only, and that every The societal perspective incorporates medical and practice was equipped with one communicator non-medical costs and health effects regardless of and a software programme for reading out the who incurs the costs and who obtains the efmonitors. fects. [34, 35] • Electronic monitor caps, the communicator and Data on healthcare utilisation, informal care, paid the software programme were depreciated in 3 house assistance, over-the-counter medication, years using the annuity method, with an interest transportation and productivity loss were collected rate of 4.5%.
[39]
using cost diaries, which were prospectively completed over three separate 4-week periods; during • The costs of the communicator and software promonths 1, 3 and 5. All resource use was collected, gramme were calculated by dividing the total irrespective of its reason. Cost diaries have proven depreciation costs per year (€242) by the mean to be a successful means to gather information on number of antihypertensive medication prescriphealthcare resource use during a longer period. [36] tions for patients without adequate BP control in Cost data were interpolated under the assumption a usual GP practice (459 per year). The mean that costs in month 1 were representative for costs in number of antihypertensive medication prescripmonth 2, and costs in month 3 and 5 were representions was determined by multiplying the average tative for costs in month 4 (i.e. month 4 costs were number of patients without adequate BP control taken as the mean of months 3 and 5). Information per usual GP practice (255) [40] by the mean numon the volume and the type of drugs obtained by ber of antihypertensive medication prescriptions per patient (1.8 per year), as observed in this were used to estimate the direct costs. [39] Informal study. care, productivity loss of unpaid work and household work were valued using the shadow-price
• The costs of the training were calculated by mulmethod. [39] Productivity loss costs for paid labour tiplying the personnel costs per minute (€0.44)
were calculated according to the friction cost by the mean duration of the training (three method, based on a mean income of the Dutch 15-minute sessions).
population according to age and gender for employThe most recent drug prices (25 May 2005) were ees. [41] obtained from an online database on medication
The healthcare costs per patient were calculated costs [37] and included the pharmacist dispensing fee. Unit prices from the Dutch manual for cost research by combining the resource utilisation data with the corresponding unit cost estimates and are reported in The cost effectiveness of electronic monitoring conversion rate).
of medication adherence was assessed in two ways: (i) by relating the difference in healthcare costs
Effects between the two strategies to the difference in the proportion of patients with NBP; and (ii) by relating the difference in societal costs between the two The effectiveness of the adherence-improving strategies to the difference in QALYs. The resulting programme was assessed in terms of the proportion point estimates, the incremental cost-effectiveness of patients with NBP at 5 months and generic QOL. ratios (ICERs), reflect the healthcare costs per pa-NBP was defined as an SBP <160mm Hg and a DBP tient with NBP and the societal costs per QALY, <95mm Hg.
respectively. Results were not extrapolated beyond Generic QOL was measured using the EQ-5D [42] the 5-month follow up and therefore discounting at baseline and at 5 months. This questionnaire was not relevant. [34, 35] contains items to measure five different dimensions of QOL: (i) mobility; (ii) self-care; (iii) daily activiAnalysis ties; (iv) pain; and (v) anxiety/depression. Based on Data were analysed according to the intention-tothe scores on the items of the EQ-5D, a population treat principle. Missing values, as a result of incomhealth state utility estimate was calculated. [43] The pleteness, were substituted by the total group obtained utility estimates were used to compute mean.
[46] Statistical significance was indicated by a QALYs, by multiplying utility by life expectancy.
p-value of <0.05. The QALY is a measure of health outcome that
In order to get insight into the uncertainty around assigns a weight ranging from 0 (worst imaginable the incremental costs, incremental effects, and health state) to 1 (best imaginable health state) for ICERs, non-parametric bootstrap simulations were each period of time.
[44] One year in perfect health conducted. [47] In a bootstrap simulation, a sample of yields one QALY. One patient could generate a cost and effect pairs of equal size of the original maximum of 0.417 QALYs, as the time horizon in sample is selected a thousand times at random with this study was 5 months. Extrapolation in time was replacement. These simulations are presented in a considered not to be valid. The QALY was estimatcost-effectiveness plane, and yield information coned using regression analysis adjusting for baseline cerning the joint distribution of the cost and effect utility, by equations 1 and 2. [45] differences. From these data 95% uncertainty intervals (UI) for cost and effect differences were calculated based on the 2.5th and 97.5th percentiles. probability that a new treatment is cost effective (Eq. 2) varies depending on the ceiling ratio used. This can where α = constant, β1 = coefficient of corrected be shown in a cost-effectiveness acceptability curve baseline utility, Utility-T0 -Utility mean = correct-(CEAC). [48] A CEAC is derived using the results ed baseline utility and β 2 = coefficient of group. BP from the bootstrap simulation, and the net-benefit and other measurements were carried out by a re-framework, [49] for different levels of ceiling ratios. search nurse in the first week, 2 months and 5 For each strategy, the net-monetary-benefit statistic months after inclusion.
is calculated by subtracting the costs valued in € from the effect multiplied by the ceiling ratio, for a low-up data were available for five patients. Four thousand simulations. Per simulation, the strategy patients refused to participate after inclusion (two with the highest net monetary benefit is preferred. due to illness, and two without giving a specific Over all simulations for each strategy, the probabili-reason), and one patient died of stroke. Of the 253 ty that a particular strategy has the highest net mone-patients (98%) with complete follow-up, 164 were tary benefit is calculated. This is repeated for a range randomised to the experimental strategy and 89 to of ceiling ratios, in order to construct the CEAC. the usual care strategy (figure 1). The mean age of The CEAC is constructed under the assumption the participants was 62 years (SD 10) in both that the willingness to pay (WTP) for health gain is groups; 59% were male in the experimental strategy identical to the willingness to accept (WTA) com-and 49% were male in the usual care strategy. On pensation for health loss. However, it has been average, 70% of the participants had paid employshown in economics that individuals do not consider ment and 77% were married in both groups. these situations identical. The amount of saving that Complete first, third and fifth month cost data will be required to accept losing health is generally were available for 139, 136 and 127 patients, respeclarger than the extra money people are prepared to tively (85%, 83% and 77%) in the experimental pay for gaining health. [50] To take this disparity into strategy and for 84, 82 and 76 patients (94%, 92% account, a CEAC was constructed with the addition and 85%) in the usual care strategy. There were no of the situation that society is not prepared to accept differences in QOL, BP, age and gender between compensation for health loss (WTA is infinite). [51] patients with complete cost diaries and patients with All analyses were performed using the Statistical missing cost data. In the experimental strategy, comPackage for the Social Sciences (SPSS) 12.0; the plete EQ-5D data were obtained from 160 patients bootstrap simulations and the CEAC were generated using Microsoft Excel.
Sensitivity Analysis
One-way sensitivity analyses were conducted on deterministic variables to provide information on the robustness of the results of the economic evaluation. Costs were assumed to be fixed and therefore were not varied. In the first analysis, the electronic monitors were provided for only one drug for 3 months, instead of for each drug for a maximum of 5 months. In the second analysis it was assumed that both the cap and the container were used only once, instead of re-use of the cap and single use of the container. In the third analysis, in order to assess whether the results were robust to a change in the method of handling missing data, we conducted a complete case analysis. The sensitivity analyses were performed under the assumption that WTP and WTA are identical.
Results
In total, 258 patients were included in the study between (98%) at baseline, and from 156 patients (95%) at 5 productivity loss costs for paid work compared with months versus 85 (95%) and 86 patients (95%), the usual care strategy. respectively, in the usual care strategy.
Effects Costs
At the end of the follow-up period, 53.7% of the patients in the experimental strategy achieved NBP, Electronic monitoring for 5 months led to a savcompared with 50.6% in the usual care strategy ing of €40 in medication costs versus usual care (table II) . This resulted in an increment of 3.1% in (95% UI -90, +8; table I). Reduction in drug costs is favour of the experimental strategy (95% UI -9.7%, achieved as a result of the statistically significant +15.8%). (p < 0.01) lower percentage of patients with drug
The mean population health state utility estimate additions and/or dose escalations in the experimenat baseline was 0.757 in the experimental strategy tal care strategy. The average costs of electronic and 0.808 in the usual care strategy. Without adjustmonitoring were €26 per patient. The communicament for the baseline utility difference, less QALYs tor and software costs amounted to €242 per year were generated in the experimental strategy comper GP practice and €0.04 per prescription per pared with the usual care strategy. Adjusting for the month. The costs of the adherence improving trainbaseline difference [46] 0.330 QALYs were yielded in ing amounted to €19.80 per patient. In total, mean the experimental care strategy versus 0.327 QALYs costs per patient directly related to the intervention in the usual care group. As a result, the incremental were €367 in the experimental strategy and €374 in QALY was 0.003 (95% UI -0.005, +0.010) in fathe usual care strategy. The mean total healthcare vour of the experimental care strategy. costs per patient amounted to €827 in the experimental strategy versus €927 in the usual care strateCost Effectiveness gy (incremental costs: €100 saved; 95% UI -€415, +€189). This cost difference is mainly caused by a From the healthcare perspective, electronic monlonger hospital stay (not related to hypertension) of itoring led to a cost saving of €100, and 3.1% more patients in the usual care strategy, which resulted in patients with NBP than with usual care. As a result, higher admission costs compared with the experi-the ICER point estimate indicated a dominance situmental care group. The mean total 5 months societal ation for this outcome parameter. The uncertainty costs per patient were slightly higher in the experi-around this outcome is visualised in the cost-effecmental strategy (€1573) than in the usual care strat-tiveness plane in figure 2. In total, 55% of the costegy (€1526); incremental costs: €47 (95% UI effectiveness replicates were situated in the south--€873, +€867). This cost difference is mainly due east (dominance) quadrant. However, the uncertainto longer health-related work absenteeism in the ty around the ICER was considerable and the repliexperimental care strategy, which resulted in higher cates were scattered over the origin. From the societal perspective, electronic moni-total, 43% of the pairs were located in the north-east quadrant, 33% in the south-east quadrant and 11% in toring resulted in extra costs of €47. This meant that the north-west quadrant. Again the uncertainty was electronic monitoring for a period of 5 months cost considerable and the pairs covered the origin. €15 667 per QALY gained. The uncertainty around the ICER point estimate showed the same pattern as
The acceptability curve is presented in figure 4 . for the clinical effectiveness measure (figure 3). In Concerning the healthcare costs per patient with NBP, the probability that the experimental strategy In the second sensitivity analysis, it was assumed is the most cost-effective alternative ranged between that the electronic monitor cap was not re-used. 75% and 80% for all ceiling ratios, assuming WTP From the healthcare perspective, as a result of the to be identical to WTA. When assuming that society increasing electronic monitoring costs, the is not willing to accept health loss, the probability probability that electronic monitoring is cost effecranged between 57% and 72%. For the societal costs tive at a ceiling ratio of €25 000, decreased from per QALY analysis, the probability of cost effec-74% to 69% for the proportion of patients with NBP tiveness ranged from 45% to 51%, depending on the as the outcome parameter. From the societal perceiling ratio and presuming WTP and WTA to be spective the probability dropped from 51% to 43% equal. This probability dropped 10% over the whole for the costs per QALY analysis at the maximum range of ceiling ratios when no compensation for ceiling ratio. health loss is accepted by society.
In the third sensitivity analysis, as the effect data were virtually complete, we conducted a complete Sensitivity analysis case analysis only for the mean total costs. In this analysis the incremental healthcare costs amounted In the first sensitivity analysis it was assumed to a saving of €150 (95% UI -€512, +€169). The that in patients who use more than one antihypertenincremental societal costs amounted to an additional sive drug, an electronic monitor was provided for €27 (95% UI -573, +597). only one drug. As this obviously results in lower costs in the experimental care group, the point estiDiscussion mate of the ICER remained to indicate a dominance situation (lower costs and more effects) from the The present study was the first economic evaluahealthcare perspective. From the societal perspec-tion of an adherence-improving programme in hytive as a result of the decreasing costs, the extra costs pertensive patients. We demonstrated that the prodecreased and the probability that electronic moni-gramme was slightly more expensive from a societal toring is cost effective was 53% at a ceiling ratio of perspective than the usual care strategy but from the €25 000 per QALY instead of 51%.
healthcare perspective it resulted in cost savings. However, it should be emphasised that the observed costs were not statistically significantly different between the groups, and that the uncertainty intervals of the differences were rather wide. The acceptability curve showed that the probability of cost effectiveness from the societal perspective (cost per QALY analysis) was rather low (47% irrespective of the ceiling ratio). It must be noted that inclusion of non-healthcare costs and use of generic QOL as the outcome parameter is especially appropriate in studies evaluating interventions in which these parameters are likely to be influenced. In this study on medication adherence in a population of patients with mild to moderate hypertension, this was not the case; the intervention had only a small impact on non healthcare costs and generic QOL. In this respect, the societal perspective might not be the most appropriate perspective. Therefore, an analysis from the healthcare perspective was also conducted. Only taking into account the healthcare the conclusion that the difference in societal costs is costs and the proportion of patients with NBP, the small and not statistically significant was not alprobability of cost effectiveness was moderate tered. (around 77%, irrespective of the ceiling ratio). A In our opinion, there are no strong reasons to cost-minimisation analysis, whereby the less costly suppose that effectiveness of the MEMS would be treatment is the preferred one, was not performed different in other countries. However, it is generally because Briggs and O'Brien [52] recommended foknown that transferability of costs to other countries cussing on the joint density of costs and effect is problematic.
[53] For instance, the price level of differences, rather than separate and sequential hymedication or the costs of use of MEMS in the GP pothesis testing in costs and effects.
practice may differ in other countries. As a conseThe sensitivity analyses demonstrated that the quence, the cost-effectiveness results cannot be results were insensitive to the number of drugs per transferred to other healthcare delivery systems patient that are electronically monitored, that the without careful consideration. costs of the electronic monitor strongly depended on
The cost effectiveness of several adherence-enre-use of the monitor cap, and that complete case hancing interventions has been assessed by analyses of costs led to similar results to mean others. [27] [28] [29] [30] [31] The majority of these studies were perimputation. Only when the cap can be used multiple formed from the patient or healthcare perspective; times in different patients did the intervention appear to be a moderately cost-effective adjustment in only one trial by Eastaugh and Hatcher [27] included the usual management of patients with hypertension the societal perspective. As in our study, this (the probability of cost effectiveness was around study [27] related costs to the proportion of patients 77%). In summary, the results strongly depend on with BP control, whereas in the other studies a the taken perspective (healthcare or societal), the specific reduction in mm Hg [29, 30] and medication outcome parameter (proportion of patient with NBP adherence improvement [30] were used as outcome or QALY) and the re-use or single use of the elec-parameters. Because of the diversity of interventions tronic monitor cap. and the use of different outcome parameters, studies in this area are difficult to compare. In the study by We chose the relatively short time horizon of 5 Friedman et al. [28] an automated telephone patient months as we supposed that the effects of MEMS monitoring and counselling system was found to be would manifest immediately (within 2 months), and a cost-effective tool to improve adherence compared the duration of the training was 3 months. Therefore, with usual care. In the study by Logan et al. [28] a we expected to capture all relevant costs within this worksite hypertension programme proved to be subperiod of time. Moreover, since the observed effect in both outcome parameters was rather small, exten-stantially more cost effective than regular care. Cansion of the time horizon beyond 1 year using a tor et al. [26] demonstrated that multiple educational modelling technique would be very difficult.
intervention combinations are not more cost effective than single interventions. The results of the A limitation of the study may be the application study by Eastaugh and Hatcher [27] showed that only of mean imputation. By imputing the group mean in a subsample of highly depressed patients do the for missing values, the variation is reduced, and the benefits of the triage method (consisting of clarificadegree of uncertainty has been underestimated. As a tion of the prescribed regimen, social support and consequence, the uncertainty interval around the increase of self confidence of the patients) outweigh cost difference may be artificially small. It seems its costs. Finally, Zarnke et al. [30] found that a palikely that the probability of cost effectiveness is an tient-directed hypertension management strategy, in optimistic estimate. Thus, the cost-effectiveness which patients measured their own BP at home, did probability of around 77% for healthcare costs per not result in a lower frequency of physician visits or QALY can be regarded as a maximum. However,
